Managing Editor
@ShahidNShah
@ShahidNShah
Why You Should Be Careful About 23andMe’s Health Test
Last month, the DNA-testing company 23andMe secured Food and Drug Administration approval for a new screening for gene-based health risks. Along with celiac disease, Alzheimer’s, Parkinson’s, breast cancer and several other medical conditions, the company can now screen clients for two mutations that have been linked to colorectal cancer.
Continue reading at nytimes.com
Make faster decisions with community advice
- Change Healthcare to focus on AI, blockchain, patient experience at HIMSS19 | Healthcare IT News
- In-Depth: Looking back at 10 years of digital health coverage | MobiHealthNews
- HIMSS TV at HIMSS19 will feature innovation leaders, former governor, Google Cloud director, and mo…
- Healthcare groups urge ONC to focus on interoperability, usability to reduce EHR burdens | FierceHe…
- Scribes save doctors time and hospitals money, new study finds | FierceHealthcare
Next Article
-
Change Healthcare to focus on AI, blockchain, patient experience at HIMSS19 | Healthcare IT News
Change Healthcare at HIMSS19 will be focusing on how intelligence can be “pushed further up into the network,” to improve healthcare overall as well as at the individual patient level, according to …
Posted Feb 4, 2019aihealthcare
